(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 23.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Dianthus Therapeutics's revenue in 2025 is $6,524,000.On average, 7 Wall Street analysts forecast DNTH's revenue for 2025 to be $103,683,782, with the lowest DNTH revenue forecast at $36,662,379, and the highest DNTH revenue forecast at $218,366,278. On average, 5 Wall Street analysts forecast DNTH's revenue for 2026 to be $130,569,527, with the lowest DNTH revenue forecast at $24,763,186, and the highest DNTH revenue forecast at $229,300,672.
In 2027, DNTH is forecast to generate $449,853,828 in revenue, with the lowest revenue forecast at $128,639,928 and the highest revenue forecast at $1,558,151,128.